Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 15;118(12):3123-7.
doi: 10.1002/cncr.26679. Epub 2012 Jan 31.

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Xuelin Huang  1 , Jorge Cortes, Hagop Kantarjian
Affiliations

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Xuelin Huang et al. Cancer. .

Abstract

Background: The annual incidence of chronic myeloid leukemia (CML) in the United States is approximately 4800 cases. With the success of tyrosine kinase inhibitor (TKI) therapy, the all-cause annual mortality rate was reduced to 2%. Therefore, the prevalence of CML is increasing over time. Estimating the CML prevalence and plateau prevalence is important in the implementation of health care strategies and future therapeutic trials. The objective of this report was to estimate the increasing prevalence and plateau prevalence of CML in future years.

Methods: The prevalence of CML was estimated based on several parameters: the annual mortality rate on TKI therapy compared with a age-matched, normal population; the incidence of CML; the anticipated population growth in the United States; and aging of the population.

Results: On the basis of these calculations, the mortality ratio of patients with CML compared with an age-matched normal population was approximately 1.53. The estimated prevalence of CML is approximately 70,000 in 2010, 112,000 in 2020, 144,000 in 2030, 167,000 in 2040, and 181,000 in 2050, when it will reach a near plateau prevalence.

Conclusions: The current results indicated that the prevalence of CML will continue to increase to reach a near plateau prevalence 35 times the annual incidence. These estimates should be considered in health care policies and in the design of future studies in CML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated prevalence of chronic myeloid leukemia in the United States by calendar year.
Figure 2
Figure 2
Survival, progression-free survival, and event-free survival with imatinib and second generation tyrosine kinase inhibitors as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia. (MD Anderson data)
Figure 2
Figure 2
Survival, progression-free survival, and event-free survival with imatinib and second generation tyrosine kinase inhibitors as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia. (MD Anderson data)
See this image and copyright information in PMC

References

    1. Arias E. United State Life Tables. National Vital Statistic Reports. 2010;58(21) http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf. - PubMed
    1. Tura S, Baccarani M, Zuffa E, et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J of Med. 1994;330:820–5. - PubMed
    1. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84 (12):4064–4077. - PubMed
    1. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355 (23):2408–2417. - PubMed
    1. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs. ST1571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood. 2009;114(22; Suppl):462. (abstract 1126)

Publication types

MeSH terms

Substances